Huntsman Carole 4

What Happened
Carole Huntsman, Chief Commercial Officer of Madrigal Pharmaceuticals (MDGL), was granted equity awards and had a small share sale. The Form 4 shows: a grant of 3,989 restricted stock units (RSUs) (acquired at $0.00), a grant of 4,986 derivative shares (acquired at $0.00, appears to be an option/other vesting award), and an open-market/private sale of 419 shares at $431.94 each, netting $180,983. The sale was reported as a withholding sale to cover taxes; the awards are subject to multi-year vesting schedules.

Key Details

• Transaction dates: grants dated March 4, 2026; sale reported March 6, 2026 (transaction dated March 4, 2026). Sale price: $431.94 per share; sale proceeds $180,983.
• Shares acquired: 3,989 RSUs and 4,986 derivative shares (grants valued at $0.00 on Form 4). Shares disposed: 419 shares.
• Shares owned after transaction: not specified in the filing.
• Notable footnotes:
  • F1: The 3,989 RSUs vest 25% on each of March 4, 2027, 2028, 2029 and 2030, subject to continued service.
  • F2: The 419-share sale was automatic — shares sold by the issuer on behalf of the reporting person to satisfy tax withholding related to vesting. It was not a discretionary market sale.
  • F3: The 4,986 derivative award vests 25% on the first anniversary (March 4, 2027) and then 6.25% each quarter thereafter, contingent on continued service.
• Filing timeliness: Form filed March 6, 2026 covering March 4 transactions; this appears to be a timely Form 4 filing.

Context
The awards are typical time-based equity compensation (RSUs and a time-vesting derivative/option grant) that vest over about four years. The 419-share sale was an issuer-facilitated sale to cover tax withholding obligations tied to vesting — a routine administrative transaction rather than an independent sell decision. These filings are informational; they show grant terms and routine withholding transactions but do not, by themselves, indicate the insider's view of the company's stock.